SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is experiencing intense downward pressure and high volatility as investors aggressively sell off precious metals, defying the traditional 'safe haven' narrative during geopolitical conflict. The community is actively debating whether this is a temporary liquidity-driven shakeout caused by margin calls and institutional rebalancing, or a fundamental shift in sentiment as the dollar strengthens and investors pivot toward high-yield alternatives.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as investors gear up for the upcoming earnings report, with heated community debate surrounding CEO compensation proposals and persistent speculation about potential large-scale acquisitions. The conversation remains heavily focused on alleged market manipulation and short-interest dynamics, keeping market participants on high alert for volatility as the earnings date approaches.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is facing extreme volatility as investors react to a federal indictment involving a company co-founder and employees in an alleged scheme to divert restricted technology to China. While some community members view the sharp sell-off as a temporary reaction to isolated bad actors, others are aggressively bearish, citing concerns over systemic management failure, potential loss of partner trust, and the risk of further regulatory intervention.

WeShop Holdings Ltd. engages in providing a shoppable social network. It offers shopping in fashion and accessories, health and beauty, home and DIY, food and drink, travel and holidays, tech and electronics, and other popular categories. It includes a library of shoppable product reviews from a digital online shopping mall on mobile devices. The company was founded by John Garner on September 21, 2012 and is headquartered in Jersey, the United Kingdom.

WeShop Holdings Ltd - Ordinary Shares - Class A

WeShop Holdings Limited

WeShop Holdings is seeing significant volatility as retail investors debate the company's unique community-owned, 'ShareBack' business model following its direct listing. While some traders are aggressively playing the stock for short-term squeezes and comparing it to previous micro-cap runners, others are skeptical of its valuation and lack of revenue, leading to intense community discussion over whether it represents a transformative platform or a potential trap.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is experiencing heightened trading activity as the market reacts to mixed earnings reports and anticipation surrounding the upcoming March 12 investor event. The community is sharply divided, with bulls pointing to the potential of a mid-size vehicle platform to drive long-term growth, while bears remain focused on persistent cash burn, dilution risks, and the company's long path toward profitability.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is experiencing intense market volatility as investors weigh the potential for a global energy supply shock against expectations of a tactical rebound in tech stocks. Market sentiment remains highly polarized, with traders debating whether escalating geopolitical tensions in the Middle East have been adequately priced in or if a deeper market correction is imminent.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart Holdings is trending as investors weigh a major strategic pivot to become a federally insured national bank against ongoing volatility and concerns regarding credit market exposure. While some market participants anticipate a potential short squeeze due to high short interest, others remain cautious as the stock continues to navigate sector-wide pressure and mixed sentiment from retail traders.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently facing significant selling pressure and heightened volatility as traders weigh concerns over the company's aggressive pivot toward physical AI and chip manufacturing against broader market anxiety regarding geopolitical tensions. Investors remain deeply divided, with many debating the feasibility of the newly announced chip infrastructure while expressing frustration over the stock's recent multi-month decline and the influence of leadership sentiment on its valuation.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

The VanEck Gold Miners ETF (GDX) is facing extreme selling pressure as investors aggressively unwind overcrowded positions amid broader market volatility and a surging US dollar. The community remains deeply divided, with some traders viewing the sharp pullback as a necessary correction to shake out weak hands before a potential resumption of the long-term uptrend, while others caution that rising energy costs and economic uncertainty could signal a deeper, more sustained reversal for the sector.

United States Commodity Funds LLC - United States Natural Gas Fund

United States Natural Gas Fund, LP

United States Natural Gas Fund ($UNG) is experiencing intense volatility as traders weigh record-breaking storage withdrawals and ongoing supply disruptions from winter storms against a looming seasonal transition. The community is heavily focused on the rapid shifts in weather models and the resulting high-stakes battle between bulls targeting a structural scarcity play and bears anticipating a spring demand collapse.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Moleculin said on Wednesday that it believes it is on track to treat the 45th subject in the first quarter of 2026, and an unblinding of data is expected thereafter.</li><li>To date, 35 subjects have been treated and another 11 are in screening or identified.</li><li>In the first 30 patients treated with Annamycin in the trial, the company reported a preliminary composite complete remission (CRc) rate of 40%.</li></ul>Shares of Moleculin Biotech, Inc., (MBRX) rose 14% on Wednesday after the company said that it is on track to treat the 45th patient with Annamycin as part of its Miracle study.The company is <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://moleculin.com/moleculin-miracle-trial-delivers-40-preliminary-blinded-crc-rate-n30/">studying</a> Annamycin in combination with cytarabine for the treatment of adult patients with acute myeloid leukemia (AML) who are refractory to or relapsed (R/R) after induction therapy.To date, 35 subjects have been treated and another 11 are in screening or identified. Site investigators are continuing to identify additional subjects and once 45 subjects are treated, the company will make its first data reveal, it said.Moleculin said on Wednesday that it believes it is on track to treat the 45th subject in the first quarter of 2026, and an unblinding of data is expected thereafter.<h2 class="st-heading-2">What Does The Data Show So Far?</h2>In the first 30 patients treated with Annamycin in the trial, the company reported a preliminary composite complete remission (CRc) rate of 40%. Composite remission (CRc) is commonly used to measure early efficacy and safety of novel agents in clinical trials.“The blinded efficacy rates we’re seeing in MIRACLE are exceptionally encouraging,” said Moleculin CEO Walter Klemp. “And, of course, this includes the control arm of cytarabine plus placebo, which suggests that the Annamycin results should be better.”Annamycin currently has Fast Track Status and Orphan Drug Designation from the FDA for the treatment of relapsed or refractory acute myeloid leukemia.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around MRX stock stayed within ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.A Stocktwits user expressed optimism for the data unblinding. “If good, it will truly be explosive,” they wrote.<stembedurl>https://www.stocktwits.com/stockadrenaline/message/645235658</stembedurl>Another user expects good days ahead.<stembedurl>https://www.stocktwits.com/Dadschuh14/message/645228970</stembedurl><a href="https://stocktwits.com/symbol/MBRX">MBRX shares</a> have lost about 89% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ibrx-gains-on-fresh-approval-for-bladder-cancer-drug-in-eu/cZR0UjXR4vV">IBRX Gains 30% On Fresh Approval For Bladder Cancer Drug In EU: Retail, Wall Street Eyes Further Rally</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did MBRX Stock Climb 14% Today?

Moleculin Biotech said on Wednesday that it is on track to treat the 45th patient with Annamycin as part of its Miracle study.

Equity

<ul class="summary-bullets"><li>The reverse split will consolidate every 25 shares of outstanding common stock into a single share, while maintaining the current par value of $0.001 per share.</li><li>The split will reduce the number of outstanding shares from roughly 51.7 million to about 2.1 million</li><li>Total authorized share count will remain unchanged at 500 million.</li></ul>&nbsp;Shares of Moleculin Biotech Inc. (MBRX) plunged over 25% on Wednesday to their lowest in five months, after the company announced a reverse stock split.Moleculin Biotech will implement a 1-for-25 reverse stock split of its common stock, effective Dec. 1, 2025, following which, the company’s shares will begin trading on a post-split basis on the Nasdaq Capital Market under the existing ticker symbol MBRX.<h2 class="st-heading-2">The Reverse Split</h2>The reverse split will consolidate every 25 shares of outstanding common stock into a single share, while maintaining the current par value of $0.001 per share. Moleculin added that it will not issue fractional shares, and any shareholder entitled to one will receive a cash payment to replace the fractional amount.The move will significantly reduce the number of outstanding shares from roughly 51.7 million to about 2.1 million, while the total authorized share count will remain unchanged at 500 million.Companies often use reverse splits to avoid being delisted, as primary exchanges require stocks to maintain a minimum price of $1.00. If a stock trades below this level for 30 straight sessions, the company receives a deficiency notice and is given a limited window to lift the share price. A reverse stock split can help the firm regain compliance and keep its listing.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/MBRX">MBRX</a> on Stocktwits remained in the ‘bearish’ territory over the past 24 hours.&nbsp;&nbsp;One user believes a share repurchase could go some way in boosting confidence.<stembedurl>https://stocktwits.com/Healthpro/message/637501819</stembedurl>MBRX stock has fallen more than 80% so far this year.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-de-stock-falling-today/cL538QhREWX">Why Is DE Stock Falling Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of stock price falling. (Photo by Yuichiro Chino/Getty Images)

Why Did MBRX Stock Plummet Over 25% Today?

Moleculin Biotech will implement a 1-for-25 reverse stock split of its common stock, effective December 1.

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions PR Newswire VANCOUVER, Oct. 21, 2025 Equity...

Moleculin Biotech (MBRX) Upgraded to Buy: Here's What You Should Know

Moleculin Biotech (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Retail chatter around Moleculin Biotech surged on Monday after the company said the European Medicines Agency had approved its Clinical Trial Application for a pivotal Phase 2B/3 study of Annamycin in combination with cytarabine for patients with relapsed or refractory acute myeloid leukemia.The European Medicines Agency approved the randomized, placebo-controlled trial in all nine European Union countries where Moleculin Biotech filed it.&nbsp;It will include research locations in the U.S. and the Middle East.&nbsp;Moleculin Biotech shares closed 2.86% higher at $1.08 on Monday, before slipping 3.7% to $1.04 in after-hours trading.Researchers will combine the Phase 2B study with Phase 3 testing to measure primary efficacy according to international regulatory requirements.Part A of the trial will recruit between 75 and 90 patients randomly assigned to receive HiDAC with a placebo or one of two FDA-approved Annamycin doses of 190 mg/m² or 230 mg/m².&nbsp;The initial patient data set from 45 participants will become available during the second semester of 2025, and researchers anticipate the second unblinding to occur at the beginning of 2026.&nbsp;The trial will expand to include approximately 220 patients during Phase 3 enrollment (Part B).EMA approval depends on Moleculin providing nonclinical GLP data before starting Part B, necessitating protocol modifications afterward.&nbsp;The trial uses an adaptive design that supports the FDA’s Project Optimus goal of improved oncology dose selection.The company remains on course to deliver its expected interim readout this year, as patient dosing has already started.On Stocktwits, retail sentiment was ‘bullish’ amid a 3,700% surge in 24-hour message volume.Some traders expressed appreciation for the stock’s steady performance, with one noting that market makers were doing a good job “keeping it tight” for those accumulating shares of Moleculin.<stembedurl>https://stocktwits.com/CrisMars/message/614378232</stembedurl>Another described the 2.86% rise of the stock as “decent” and said “low and slow will win the race.”<stembedurl>https://stocktwits.com/BiggPapa/message/614389064</stembedurl>The stock has declined nearly 39% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Moleculin Biotech Gets EMA Nod For Leukemia Trial: Retail Feels Bullish On ‘Low And Slow’ Setup 

The trial, which will involve sites in the U.S., Europe, and the Middle East, aims to combine Phase 2B and Phase 3 data for efficacy evaluation of the Miracle trial of Annamycin for relapsed or refractory acute myeloid leukemia.

AIM ImmunoTech, Inc. (1100% jump in message volume)AIM ImmunoTech surged in retail discussions after announcing the first new subject was dosed in Phase 2 of its Phase 1b/2 trial for Ampligen and AstraZeneca’s (AZN) Imfinzi in late-stage pancreatic cancer treatment. Several Phase 1 patients who received the highest dose will also be included in Phase 2. The trial, known as DURIPANC, is taking place in the Netherlands and will enroll up to 25 patients in this phase.PepGen, Inc. (700% jump in message volume)PepGen shares and retail chatter <a href="https://stocktwits.com/news-articles/markets/equity/pepgen-stock-heads-for-best-week-since-sept-2022/chdghv2RyH">soared</a> after the company released early clinical data from its FREEDOM-DM1 Phase 1 trial for PGN-EDODM1 in myotonic dystrophy type 1 (DM1), a genetic disorder causing progressive muscle weakness. The company reported dose-dependent splicing correction of 12.3% at 5 mg/kg and 29.1% at 10 mg/kg at 28 days post-dosing.While single-dose studies haven’t shown functional improvements, PepGen sees early signs of benefits with repeat dosing. H.C. Wainwright called the data “very encouraging.”Aeon Biopharma, Inc. (700% jump in message volume)Aeon gained attention after announcing a 1-for-72 reverse stock split to meet NYSE American’s minimum share price requirement. The move took effect on Wednesday, with fractional shares rounded up.Last month, Aeon received a non-compliance notice from NYSE American for failing to meet the $2 million stockholders’ equity requirement. The company reported a $32.1 million stockholders’ deficit as of Sept. 30 and has suffered losses in its last two fiscal years. Aeon has until March 5 to submit a plan to regain compliance.Tiziana Life Sciences Ltd. (600% jump in message volume)Tiziana’s stock buzz jumped after a Nature Neuroscience study showed its nasal anti-CD3 monoclonal antibody significantly reduced neuroinflammation and improved recovery in a preclinical model of traumatic brain injury (TBI). The treatment correlated with less anxiety, reduced cognitive decline, and improved motor skills.Additionally, Tiziana revealed on Tuesday that its nasal anti-CD3 preclinical study is nearing completion and that foralumab could be a novel treatment for long COVID.Moleculin Biotech, Inc.&nbsp;(600% jump in message volume)Moleculin saw heightened retail discussion after announcing a $1.07 per share direct offering of about 3.3 million shares and warrants to an institutional investor, with 6.5 million warrants exercisable at $1.07 per share for five years.The company&nbsp;expected to close the offering on Feb. 26, with Roth Capital Partners as the placement agent. The company said proceeds would be used for working capital and general corporate purposes.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week

New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.

These five biotech stocks, all belonging to nano-, small- or mid-cap categories, notched the highest jump in Stocktwits message volume in the week ended Feb. 14, 2025:GlycoMimetics Inc. (+550% jump in chatter)GlycoMimetics, a late-stage biotech firm developing glycobiology-based cancer therapies, saw a surge in retail interest after a minor amendment to its merger agreement with Crescent Biopharma. The update refined the financing structure but kept intact the exchange ratio and ownership split. Once the deal closes, Crescent security holders, including new investors, will own about 96.9% of the combined company. Shares are up roughly 16% year-to-date (YTD).GRAIL Inc. (+500% jump in chatter)Cancer detection firm GRAIL made waves after announcing a partnership with Quest Diagnostics (DGX) to distribute its Galleri multi-cancer early detection test. Analysts at Guggenheim viewed the move as a major step toward broader accessibility. The stock has soared over 208% YTD.ADMA Biologics Inc. (+400% jump in chatter)ADMA Biologics, a biopharma company focused on plasma-derived therapies, saw rising buzz ahead of its upcoming fourth-quarter (Q4) earnings. Last month, it issued a preliminary report projecting full-year 2024 revenue between $417 million and $425 million, with total cash holdings exceeding $100 million. Despite the strong forecast, shares remain down more than 8% YTD.Moleculin Biotech Inc. (+295% jump in chatter)Moleculin Biotech gained traction after the FDA provided guidance on its Phase 3 trial for Annamycin, a next-generation anthracycline designed to treat relapsed/refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases. With an adjusted trial size, the company expects its first unblinding in late 2025 and another in early 2026. Shares have climbed over 25% YTD.Exelixis Inc. (+200% jump in chatter)Exelixis, an oncology-focused biotech, saw a surge in discussions after reporting Q4 earnings that topped estimates, prompting analysts to raise their price targets. Citi highlighted continued strength in its Cabometyx franchise and pointed to Zanza as a potential blockbuster drug. Shares are up 4.35% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Top 5 Biotech Stocks That Got Most Retail Buzz Last Week

From merger updates to earnings surprises, these healthcare stocks saw the biggest spike in Stocktwits chatter.

This account has been verified as an official MBRX representative.

Verified Account

Moleculin Biotech

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe in July 2015 and is headquartered in Houston, TX.

MBRX
Moleculin Biotech Inc

Feed

News

Sentiment

Fundamentals

Info

Latest MBRX News

MBRXMoleculin Biotech Inc